EN DE
  • Paion GmbH
  • Company

    About PAION

    1. History
    2. Management
  • Insolvency Proceedings
  • Media and Investors

    At a glance

    1. General Information

    Newsroom

    1. Press Releases
    2. Ad-hoc Releases
    3. Directors' Dealings
    4. Holdings in company

    Information on shares

    1. Chart & Fact sheet
    2. Analysts
    3. Capital actions
    4. Information on CeNeS Acquisition

    Investorcenter

    1. Financial Reports
    2. Presentations
    3. Corporate calendar

    Corporate Governance

    1. Declaration on Corporate Governance
    2. Articles of Association
    3. Declaration of Conformity
    4. Code of Conduct
    5. By-Laws Supervisory Board
    6. Compensation Management Board and Supervisory Board

    Annual general meeting

    2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
  • Contact

    Germany

    UK

    Netherlands

Here you will find information on PAION AG i.L. relevant to stock corporation and stock exchange law.

The operating business of PAION AG i.L. and PAION Deutschland GmbH i.L. has been transferred to PAION Pharma GmbH as part of the insolvency proceedings.

You can reach PAION Pharma GmbH at www.paionpharma.com

  • Media and Investors
  •  »  Newsroom
  •  »  Press Releases
  •  »  2008
  • 12/22/2008

    Press release: PAION and ERGOMED complete enrolment of Phase IIa study with CNS 5161 in opioid-refractory cancer pain

    • PDF

  • 12/17/2008

    Press release: PAION's partner Lundbeck initiates clinical phase III trials with Desmoteplase in ischaemic stroke

    • PDF

  • 11/19/2008

    Press release: PAION announces successful completion of Phase I study with the sedative/anaesthetic CNS 7056

    • PDF

  • 11/05/2008

    Press release: PAION AG reports nine-months results 2008

    • PDF

  • 11/03/2008

    Press release: PAION sees improved probability of success for pain drug M6G following successful meta-analysis of clinical data

    • PDF

  • 09/22/2008

    Press release: PAION announces Phase I study with sedative/anaesthetic CNS 7056 progressed to midazolam comparison

    • PDF

  • 08/11/2008

    Press release: PAION AG reports results for the first half-year 2008 and provides strategy update

    • PDF

  • 07/31/2008

    New Supervisory Board Member appointed

    • PDF

  • 07/25/2008

    Press release: PAION announces dosing of first healthy volunteers in Phase I study with its sedative/anaesthetic CNS 7056

    • PDF

  • 07/25/2008

    Regulatory release: Announcement according to Sec 37w WpHG: Publication date for half-year report 2008

    • PDF

  • 07/09/2008

    Press release: PAION announces plan to commence clinical program with its sedative CNS 7056

    • PDF

  • 06/23/2008

    Ad hoc & press release: PAION AG completes acquisition of CeNeS

    • PDF

  • 06/20/2008

    Press release: Court sanctions Scheme of Arrangement for acquisition of CeNeS

    • PDF

  • 05/28/2008

    Press release: shareholders of CeNeS vote for acquisition by PAION

    • PDF

  • 05/21/2008

    PAION's anticoagulant Solulin achieves proof of concept for mode of action in Phase I

    • PDF

  • 05/06/2008

    Press release: PAION Annual General Meeting and CeNeS Acquisition Update

    • PDF

  • 04/29/2008

    Press release: PAION AG reports results for the first quarter 2008

    • PDF

  • 04/23/2008

    Press release: PAION AG acquires world-wide rights to anticoagulant flovagatran from UK company Trigen

    • PDF

  • 04/10/2008

    Ad hoc & press release: PAION AG intends to acquire CeNeS Pharmaceuticals plc

    • PDF

  • 03/03/2008

    Press release: PAION AG reports financial results for fiscal year 2007

    • PDF

  • 02/28/2008

    PAION's anticoagulant Solulin successfully tested in first-in-man study

    • PDF

  • 01/29/2008

    Ad hoc & press release: PAION agreement with Lundbeck comes into force

    • PDF

  • copyright © PAION AG I all rights reserved
  • Imprint
  • Privacy Statement
  • General Terms and Conditions
Paion

Heussstraße 25 | 52078 Aachen | Deutschland

Tel.: +49 241 4453-0 | Fax.: +49 241 4453-100 | e-mail: info@paion.com

Company
  1. About PAION +
    1. History
    2. Management
Insolvency Proceedings
Media and Investors
  1. At a glance +
    1. General Information
  2. Newsroom +
    1. Press Releases
    2. Ad-hoc Releases
    3. Directors' Dealings
    4. Holdings in company
  3. Information on shares +
    1. Chart & Fact sheet
    2. Analysts
    3. Capital actions
    4. Information on CeNeS Acquisition
  4. Investorcenter +
    1. Financial Reports
    2. Presentations
    3. Corporate calendar
  5. Corporate Governance +
    1. Declaration on Corporate Governance
    2. Articles of Association
    3. Declaration of Conformity
    4. Code of Conduct
    5. By-Laws Supervisory Board
    6. Compensation Management Board and Supervisory Board
  6. Annual general meeting +
    1. 2023
    2. 2022
    3. 2021
    4. 2020
    5. 2019
    6. 2018
    7. 2017
    8. 2016
    9. 2015
    10. 2014
    11. 2013
    12. 2012
    13. 2011
Contact
  1. Germany
  2. UK
  3. Netherlands
Cookie Settings

This website uses cookies.

Some of them are essential and required for running the website. Others improve your user experience and may be activated or deactivated at your discretion.

Accept all Save
Privacy Statement Imprint